• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

靶向拓扑异构酶II的抗癌药物的临床应用

Clinical applications of anticancer drugs targeted to topoisomerase II.

作者信息

Hande K R

机构信息

Department of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-5536, USA.

出版信息

Biochim Biophys Acta. 1998 Oct 1;1400(1-3):173-84. doi: 10.1016/s0167-4781(98)00134-1.

DOI:10.1016/s0167-4781(98)00134-1
PMID:9748560
Abstract

Agents which 'poison' the enzyme topoisomerase II, have proven to be useful drugs for cancer treatment. Six antineoplastic drugs, which target topoisomerase II (doxorubicin, daunorubicin, idarubicin, mitoxantrone, etoposide and teniposide) are currently approved for clinical use in the United States. In this paper, the strategies and goals of cancer chemotherapy are summarized for the non-clinician. The use, pharmacology and toxicity of each of the six currently approved topoisomerase II inhibiting agents are reviewed.

摘要

已证实，能够“毒害”拓扑异构酶II的药物是治疗癌症的有效药物。目前，美国已批准六种靶向拓扑异构酶II的抗肿瘤药物（多柔比星、柔红霉素、伊达比星、米托蒽醌、依托泊苷和替尼泊苷）用于临床。本文为非临床医生总结了癌症化疗的策略和目标。对目前已批准的六种拓扑异构酶II抑制剂的用途、药理学和毒性进行了综述。

相似文献

1
Clinical applications of anticancer drugs targeted to topoisomerase II.靶向拓扑异构酶II的抗癌药物的临床应用
Biochim Biophys Acta. 1998 Oct 1;1400(1-3):173-84. doi: 10.1016/s0167-4781(98)00134-1.
2
Toxicity of the topoisomerase II inhibitors.拓扑异构酶II抑制剂的毒性
Expert Opin Drug Saf. 2005 Mar;4(2):219-34. doi: 10.1517/14740338.4.2.219.
3
Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.喜树碱和鬼臼毒素衍生物：拓扑异构酶I和II抑制剂——作用机制、药代动力学及毒性特征
Drug Saf. 2006;29(3):209-30. doi: 10.2165/00002018-200629030-00005.
4
Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.拓扑异构酶II抑制剂对核因子-κB激活和功能的差异调节
BMC Cancer. 2006 Apr 21;6:101. doi: 10.1186/1471-2407-6-101.
5
Etoposide: four decades of development of a topoisomerase II inhibitor.依托泊苷：一种拓扑异构酶II抑制剂四十年的发展历程
Eur J Cancer. 1998 Sep;34(10):1514-21. doi: 10.1016/s0959-8049(98)00228-7.
6
Topoisomerase inhibitors. A review of their therapeutic potential in cancer.拓扑异构酶抑制剂。对其在癌症治疗中的潜在作用的综述
Drugs. 1995 Jan;49(1):11-9. doi: 10.2165/00003495-199549010-00002.
7
Mitoxantrone, More than Just Another Topoisomerase II Poison.米托蒽醌，不仅仅是另一种拓扑异构酶 II 抑制剂。
Med Res Rev. 2016 Mar;36(2):248-99. doi: 10.1002/med.21364. Epub 2015 Aug 19.
8
DNA topoisomerase II inhibitors.DNA拓扑异构酶II抑制剂
IARC Monogr Eval Carcinog Risks Hum. 2000;76:175-344.
9
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.DNA拓扑异构酶及其被抗癌和抗菌药物抑制的情况。
Chem Biol. 2010 May 28;17(5):421-33. doi: 10.1016/j.chembiol.2010.04.012.
10
Clinical development of topoisomerase-interactive drugs.拓扑异构酶相互作用药物的临床开发。
Adv Pharmacol. 1994;29B:1-31. doi: 10.1016/s1054-3589(08)61129-1.

引用本文的文献

1
Scalable production of human cortical organoids using a biocompatible polymer.使用生物相容性聚合物可扩展生产人类皮质类器官。
Nat Biomed Eng. 2025 Jun 27. doi: 10.1038/s41551-025-01427-3.
2
Dual-Action Therapeutics: DNA Alkylation and Antimicrobial Peptides for Cancer Therapy.双作用疗法：用于癌症治疗的DNA烷基化与抗菌肽
Cancers (Basel). 2024 Sep 10;16(18):3123. doi: 10.3390/cancers16183123.
3
Development and validation of a UPLC-MS/MS method for simultaneous detection of doxorubicin and sorafenib in plasma: Application to pharmacokinetic studies in rats.
一种用于同时检测血浆中多柔比星和索拉非尼的超高效液相色谱-串联质谱法的开发与验证：在大鼠药代动力学研究中的应用
Saudi Pharm J. 2023 Jul;31(7):1317-1326. doi: 10.1016/j.jsps.2023.05.025. Epub 2023 Jun 1.
4
DNA damage independent inhibition of NF-κB transcription by anthracyclines.蒽环类药物通过非 DNA 损伤途径抑制 NF-κB 转录。
Elife. 2022 Dec 7;11:e77443. doi: 10.7554/eLife.77443.
5
Anthraquinones as Inhibitors of SOS RAS-GEF Activity.蒽醌类化合物作为 SOS RAS-GEF 活性的抑制剂。
Biomolecules. 2021 Jul 30;11(8):1128. doi: 10.3390/biom11081128.
6
Synthesis of novel, DNA binding heterocyclic dehydroabietylamine derivatives as potential antiproliferative and apoptosis-inducing agents.新型 DNA 结合型脱氢枞胺杂环衍生物的合成及其作为潜在的抗增殖和诱导凋亡试剂。
Drug Deliv. 2020 Dec;27(1):216-227. doi: 10.1080/10717544.2020.1716879.
7
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.M3814（一种口服 DNA-PK 抑制剂）与拓扑异构酶 II 抑制剂联合在卵巢癌模型中的活性。
Sci Rep. 2019 Dec 11;9(1):18882. doi: 10.1038/s41598-019-54796-6.
8
Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology.癌胚 HMGA2 通过调节局部 DNA 拓扑结构来减轻拓扑异构酶 II 靶化合物引起的遗传毒性损伤。
Mol Oncol. 2019 Oct;13(10):2062-2078. doi: 10.1002/1878-0261.12541. Epub 2019 Aug 31.
9
Emerging small-molecule treatments for multiple sclerosis: focus on B cells.多发性硬化症的新兴小分子治疗方法：聚焦于B细胞。
F1000Res. 2019 Mar 1;8. doi: 10.12688/f1000research.16495.1. eCollection 2019.
10
Evaluation of intraductal delivery of poly(ethylene glycol)-doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)-like lesions in rats.聚乙二醇-阿霉素共轭纳米载体导管内给药治疗大鼠原位导管癌（DCIS）样病变的评估。
J Interdiscip Nanomed. 2018 Oct 15;3(3):146-159. doi: 10.1002/jin2.51. eCollection 2018 Sep.